I. GOALS

The goal of the ACTEMRA REMS is:

D To inform healthcare providers about the serious risks associated with ACTEMRA.

II. REMS ELEMENTS

A. Communication Plan (FDCA Section 505-1(e)(3))

In accordance with FDCA 505-1(e)(3), Genentech, A Member of the Roche Group, will implement a communication plan to the following adult and pediatric healthcare providers:

D Rheumatologists and rheumatology healthcare providers who are likely to prescribe ACTEMRA
D Infectious disease specialists who may be consulted about serious infection
D Gastroenterologists and hepatologists who may be consulted about gastrointestinal perforation, hepatic disease, or hepatic impairment
D Family practitioners, general practitioners, osteopaths, internists, and internal medicine specialists who may be consulted about serious infections, gastrointestinal perforations, changes in liver function, decreases in peripheral neutrophil counts, decreases in platelet counts, elevations in lipid parameters in peripheral blood, demyelinating disorders, and malignancies associated with ACTEMRA
D Emergency medicine specialists who may treat serious infections, gastrointestinal perforations, and changes in liver function
D Neurologists who may treat demyelinating disorders
D Oncologists who may treat malignancies

Elements of the communication plan include the following:

1. A Dear Healthcare Provider Letter (see Attachment A) will be distributed to adult and pediatric prescribers to include rheumatologists, gastroenterologists, hepatologists, neurologists, oncologists, infectious disease specialists, family medicine specialists, internal medicine specialists, emergency medicine specialists, and to infusion sites. This letter will be distributed within 60 days of approval of a new indication or new dosage form.

A Professional Label that includes the Medication Guide will also be distributed in this communication.

2. Prescriber Education Slide Deck

The prescriber education slide deck will provide information about specific safety risks (including, but not limited to, demyelination, malignancy, laboratory parameters and dosage modifications, and hypersensitivity reactions, including anaphylaxis) associated with ACTEMRA.

The slides will be available within 60 days of REMS modification approval through the following distribution methods:

D The www.ACTEMRAREMS.com website (see Attachment J for the REMS Website landing page screenshot)

D Genentech Rheumatology Medical Science Liaison (MSL) will conduct educational sessions presenting these slides to rheumatology prescribers of ACTEMRA.

D Hard copy mailing, upon request, through Genentech’s toll-free medical information line (1-800-228-3672)

The prescriber education slide deck will be available for 3 years following approval of the REMS Modification. The prescriber education slide deck is appended to this document (see Attachment B)

3. Dissemination of information about the known and potential risks associated with ACTEMRA to healthcare providers through certain professional societies’ scientific meetings and journals:

a) For display as a panel/poster and distribution as printed material at major convention meetings of rheumatologists and other healthcare professionals specializing in rheumatology where the company has a sponsored booth for 2 years following product approval (completed January 2012).

c) For quarterly presentation as a printed information piece in the *Journal of Clinical Oncology* for 5 years following product approval (through January 2015).

The REMS journal information piece is appended to this document (see Attachments C, D, E, F, G, H and I).

4. Genentech will ensure that all materials listed in or appended to the ACTEMRA REMS program will be available through the ACTEMRA REMS program website www.ACTEMRAREMS.com or by calling 1-800-228-3672. The ACTEMRA REMS program website will exist for 3 years following approval of the REMS Modification. The landing page for the ACTEMRA REMS program website is appended to this document (see Attachment J).

**B. Timetable for Submission of Assessments**

REMS assessments will be submitted to FDA at 18 months, 3 years, 5 years, and 7 years after approval of the original REMS (January 8, 2010). To facilitate inclusion of as much information as possible while allowing reasonable time to prepare the submission, the reporting interval covered by each assessment will conclude no earlier than 60 days before the submission date so that it will be received by the FDA on or before the due date.